Protecting Access to Medicare Act

Signed into law on April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) includes the most extensive reform of the Medicare Clinical Laboratory Fee Schedule (CLFS) since it was established in 1984. Section 216 of PAMA creates a new Section 1834A of the Social Security Act, which contains many of the CLFS…

Signed into law on April 1, 2014, the Protecting Access to Medicare Act of 2014 (PAMA) includes the most extensive reform of the Medicare Clinical Laboratory Fee Schedule (CLFS) since it was established in 1984. Section 216 of PAMA creates a new Section 1834A of the Social Security Act, which contains many of the CLFS reforms. Starting on January 1, 2017, most rates on the CLFS will be derived from private payor rates for laboratory services. PAMA also designates certain tests as “advanced diagnostic laboratory tests” (ADLTs); includes provisions affecting coding, coverage and oversight of the CLFS; and makes some changes to CMS’s review of mis-valued codes in the Physician Fee Schedule (PFS) affecting anatomic pathology services provided by laboratories.

Click here for a summary of CLFS reform provisions in PAMA.

Read More

  • ACLA Statement on Final 2019 Medicare Payment Policies

    November 02, 2018
    Final rule takes preliminary steps to correct flawed data collection process; urgent Congressional action needed to protect millions of seniors from continued cuts to essential Medicare lab services   Washington, D.C. – Following the release of final Medicare payment policies, Julie Khani, President of the American Clinical Laboratory Association (ACLA) issued the following statement regarding new policy changes related to implementation of the Protecting AccessContinue Reading »...
  • PAMA Frequently Asked Questions (FAQs)

    October 26, 2018
    ...
  • ACLA Statement on Notice of Appeal in ACLA v. Azar

    October 19, 2018
    HHS’s continued reliance on faulty data collection process jeopardizes access to critical lab tests for millions of beneficiaries; ACLA files appeal following District Court decision  Washington, D.C. – Today, the American Clinical Laboratory Association (ACLA) filed its notice of appeal in its lawsuit against the U.S. Department of Health and Human Services (HHS) challenging its implementation of the Protecting Access to Medicare Act (PAMA),Continue Reading »...
  • ACLA Statement on District Court Opinion in Lawsuit Against HHS

    September 24, 2018
    Lawsuit targeted HHS’ unlawful implementation of 2014 Medicare legislation, regulatory guidance that would jeopardize beneficiaries’ access to critical lab services Washington, D.C. – Following the opinion from the U.S. District Court for the District of Columbia in ACLA v. Azar, Julie Khani, ACLA President, issued the following statement: “This is an extremely disappointing outcome for ACLA’s members and the millions of seniors they serveContinue Reading »...
  • Press Release; ACLA Submits Comments to Proposed 2019 Medicare Payment Policies

    September 11, 2018
    ...
  • ACLA Comments on CY 2019 PFS Proposed Rule

    September 11, 2018
    ...
  • Leading Patient, Provider, Diagnostic and Laboratory Organizations Call on Congress to Protect Seniors from Medicare Lab Cuts

    August 02, 2018
    HHS’ flawed data collection system jeopardizes beneficiary access to critical lab services Washington, D.C. – With millions of Medicare beneficiaries facing year-over-year cuts to their Medicare lab access, more than 30 leading organizations representing patients, health care professionals, laboratories and diagnostic manufacturers urged Congressional leaders to take immediate action to prevent drastic reductions to beneficiaries’ care. The letter reiterates the serious concerns regarding theContinue Reading »...
  • PAMA Stakeholder Letter to Congress

    August 02, 2018
    ...
  • Market-Based in Practice, Not Just Theory

    July 26, 2018
    One of the driving forces in today’s health system is the goal of promoting and maintaining a competitive market for patients. In a “market-based” health system, consumers see the direct benefit of labs competing on quality, cost and services available – rather than an arbitrary, one-size-fits-all approach that fails to achieve any of these goals. In fact, that was one of the prevailing incentivesContinue Reading »...
  • ACLA Statement on HHS OIG Report Regarding PAMA Cuts & Data Collection

    July 19, 2018
    Washington, D.C. – Following the release of today’s report from the U.S. Department of Health & Human Services (HHS) and the Office of Inspector General (OIG) regarding laboratory data collection under The Protecting Access to Medicare Act of 2014 (PAMA), Julie Khani, President of the American Clinical Laboratory Association (ACLA), released the following statement: “Today’s OIG report skirts the central issue: that HHS deliberatelyContinue Reading »...
1 2 3 4 5 6 7